Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1)
Conditions
Interventions
Plinabulin
Pegfilgrastim
Locations
19
United States
Emad Ibrahim, MD, Inc.
Redlands, California, United States
Mid Florida Hematology & Oncology Center
Orange City, Florida, United States
Cancer Center of Middle Georgia
Dublin, Georgia, United States
Hematology/Oncology of the North Shore
Skokie, Illinois, United States
Harbin Medical University Cancer Hospital
Harbin, Harbin, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Start Date
April 5, 2017
Primary Completion Date
March 20, 2018
Completion Date
April 20, 2018
Last Updated
May 16, 2024
NCT06537726
NCT05245487
NCT04101760
NCT03251768
NCT02454530
NCT03559387
Lead Sponsor
BeyondSpring Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions